Xavier AVAT - 28 Mar 2023 Form 4 Insider Report for CAPRICOR THERAPEUTICS, INC. (CAPR)

Role
FORMER CHIEF BUSINESS OFFICER
Signature
/s/ Linda Marban, Attorney-in-Fact
Issuer symbol
CAPR
Transactions as of
28 Mar 2023
Net transactions value
-$12,183
Form type
4
Filing time
07 Apr 2023, 17:00:16 UTC
Previous filing
07 Jul 2022
Next filing
27 Apr 2023
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction CAPR Common Stock Sale $12,180 -3,000 -100% $4.06 0 28 Mar 2023 Direct
transaction CAPR Common Stock Options Exercise $293,377 +84,791 $3.46 84,791 05 Apr 2023 Direct
transaction CAPR Common Stock Tax liability $293,380 -70,019 -83% $4.19 14,772 05 Apr 2023 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction CAPR Stock Option (Right to Buy) Options Exercise $0 -84,791 -100% $0.000000* 0 05 Apr 2023 Common Stock 84,791 $3.46 Direct F2, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Xavier AVAT is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may continue.

Explanation of Responses:

Id Content
F1 Represents a "net exercise" of outstanding stock options. These shares were withheld by the Issuer for payment of the exercise price, based on the closing market price of the Issuer's common stock on April 5, 2023 of $4.19.
F2 The shares vested 1/48th of the first day of each month, commencing June 1, 2022.
F3 The option expires 90 days following the termination of Mr. Avat's employment with the Company. Mr. Avat's employment terminated on April 7, 2023. While the box indicating that Mr. Avat is no longer subject to Section 16 has been checked, Mr. Avat remains subject to Section 16 through such date.